Reported about 9 hours ago
AbCellera Biologics Inc. (NASDAQ:ABCL) is making significant strides in its transition from discovery to clinical execution, highlighted by its recent appointment of Dr. Sarah Noonberg as Chief Medical Officer. This move aims to accelerate the company's expansion into immunological diseases while advancing its AI-driven antibody therapies, including two new treatments currently in Phase 1 trials. With an increasing pipeline of 16 molecules in clinical development, AbCellera is poised for further growth and plans to launch additional clinical trials by the end of 2025.
Source: YAHOO